AN2 Therapeutics Inc
Research AN2 Therapeutics Inc (ANTX) on Bullrun: market cap USD 205.51M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 205.51M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 10.03M
- Free cash flow-USD 12.07M
Valuation Snapshot
latest market cap is USD 205.51M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 35.17M | -USD 29.83M | n/a | -1.16 | USD 19.94M | n/a | USD 53.06M |
| FY2024 | USD 0 | -USD 51.32M | -USD 49.26M | n/a | -1.72 | USD 21.35M | n/a | USD 81.85M |
| FY2023 | USD 0 | -USD 64.73M | n/a | n/a | -2.74 | USD 15.65M | USD 0 | USD 124.70M |
| FY2022 | n/a | -USD 40.96M | n/a | n/a | -2.79 | USD 27.22M | USD 53.00K | USD 95.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 205.51M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 31.25M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 41.29M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 609.40M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 184.91M | n/a | n/a | n/a |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AN2 Therapeutics Inc's market cap?
AN2 Therapeutics Inc's market capitalization is USD 205.51M.
What does AN2 Therapeutics Inc do?
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.